RxDoctor Payments Data

Brian Yeh, MD

Radiation Oncology · Flint, MINPI 1265762777

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Boston Scientific at 51.6% of the total. That places this record below the midpoint for radiation oncology clinicians in MI, where the typical reported total is $354.

$83in general payments, 2019–2025

Across 3 payments — averaging $27.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$43
  • Bioprotect Medical, Inc.$26
  • Novartis$14
$20,200in research payments, 2019–2025

Across 7 payments — averaging $2885.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$20K

What the payments were for

  • Food & beverage$83100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$83 in reported general payments places this provider in the 20th percentile of 198 radiation oncology providers in Michigan.

See all radiation oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$245,414
Medicare patients
312
Services billed
2,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$5,669
Tamsulosin Hcl68$1,008
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$263
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$176
Hydromorphone Hcl14$146
Medroxyprogesterone Acetate11$105

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →